{"id":"W4415424866","doi":"10.1002/ejhf.70069","title":"<i>European Journal of Heart Failure</i> Consensus Statement. Heart Failure Pharmacotherapy for Patients with Heart Failure with Reduced Ejection Fraction and Concomitant Atrial Fibrillation: Review of Evidence and Call to Action","year":2025,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Heart Institute; Surgical Specialties (Canada)","funders":"National Heart, Lung, and Blood Institute; Cardio-Pulmonary Institute; H. Lundbeck A/S; Novo Nordisk; Roche; Deutsche Forschungsgemeinschaft; Eli Lilly and Company; Boehringer Ingelheim España; Daiichi Sankyo Europe; Servier; Horizon Therapeutics; Pfizer; Moderna; Medtronic; Cytokinetics; AstraZeneca; Amarin Corporation; Boston Scientific Corporation; Novo Nordisk USA; Bayer HealthCare; European Commission; Sanofi; National Institutes of Health; Regeneron Pharmaceuticals; Novartis; Bristol-Myers Squibb; Boehringer Ingelheim; Amgen","keywords":"Heart failure; Atrial fibrillation; Pharmacotherapy; Concomitant; Context (archaeology); Ejection fraction; Spironolactone; Comorbidity; Cardiac resynchronization therapy; Call to action","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006694703,0.001175997,0.00324699,0.004379281,0.0007472663,0.002755833,0.003782078,0.004644321,0.01256393],"category_scores_gemma":[0.01617316,0.0005879806,0.003626875,0.003889981,0.0009981733,0.00244551,0.002294234,0.004626906,0.007536185],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002055768,"about_ca_system_score_gemma":0.009702999,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005923868,"about_ca_topic_score_gemma":0.00873423,"domain_scores_codex":[0.9965709,0.0007252838,0.001081072,0.0002394964,0.001168634,0.000214497],"domain_scores_gemma":[0.9832303,0.006583473,0.003680619,0.0002339117,0.005480499,0.0007911858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001680892,0.00004253877,0.0003793334,0.05127267,0.000432838,0.0001127297,0.00009016542,0.0001201787,0.0002632271,0.001831926,0.7039773,0.241309],"study_design_scores_gemma":[0.0001953702,0.00009108008,0.002732977,0.1127422,0.0008686986,0.0004678824,0.000107228,0.0001156466,0.000167987,0.002008549,0.8804564,0.00004601368],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002126657,0.8834438,0.001000358,0.07738418,0.02525572,0.000505034,0.00312971,0.0001178657,0.008950708],"genre_scores_gemma":[0.002468773,0.889351,0.004044358,0.07125232,0.01935949,0.00128189,0.005982424,0.00007677152,0.006183075],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01256393,"threshold_uncertainty_score":0.04203057,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05293365401045189,"score_gpt":0.3493672729555577,"score_spread":0.2964336189451058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}